Correspondence Methemoglobinemia as a Complication of Topical Dapsone Published January 29, 2015 N Engl J Med 2015;372: 491 - 492 DOI: 10.1056/NEJMc1408272 ...

Feb. 13, 2006 — The US Food and Drug Administration (FDA) has issued a health advisory to warn healthcare professionals of the risk for methemoglobinemia associated with use of benzocaine sprays ...

(HealthDay News) — Use of topical dapsone may have led to the development of methemoglobinemia, according to a case study published in the Jan. 29 issue of the New England Journal of Medicine.

Methemoglobinemia is a potentially fatal condition caused by the presence of the oxidized ferric (Fe 3+) heme that leads to poor oxygen delivery to tissues. It can be congenital but is usually ...

With methemoglobinemia, the hemoglobin can carry oxygen, but is not able to release it effectively to body tissues. The disorder is sometimes passed down through families.

Jianjun Liu from the A*STAR Genome Institute of Singapore and his colleagues performed a genome-wide association study involving 872 individuals who had received dapsone as part of a multi-drug ...

Dapsone was given in a stepwise manner at 25 mg daily for 3 days, followed by 50 mg daily for 3 days, 75 mg daily for 3 days, and 100 mg daily for 1 week. If the patient had a low hemoglobin level ...

Genomewide association analysis showed that SNP rs2844573, located between the HLA-B and MICA loci, was significantly associated with the dapsone hypersensitivity syndrome among patients with ...